NASDAQ : CNSP
CNS Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.75 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 6.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.31M |
| Enterprise Value | -12.68M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.46M |
| Shares Outstanding | 1.46M |
| Shares Change (YoY) | +1,105.07% |
| Shares Change (QoQ) | +911.31% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 13.54% |
| Float | 1.32M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.86 |
| Quick Ratio | 5.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,110.61 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -106.62% |
| Return on Assets (ROA) | -58.01% |
| Return on Invested Capital (ROIC) | -67.23% |
| Return on Capital Employed (ROCE) | -92.94% |
| Weighted Average Cost of Capital (WACC) | 9.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.09M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -34.21% |
| 50-Day Moving Average | 5.36 |
| 200-Day Moving Average | 4.60 |
| Relative Strength Index (RSI) | 48.71 |
| Average Volume (20 Days) | 16,025 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1,300 |
| Short Previous Month | 898 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.91M |
| Pretax Income | -16.70M |
| Net Income | -16.70M |
| EBITDA | -16.90M |
| EBIT | -16.91M |
| Earnings Per Share (EPS) | -$7.66 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 19.99M |
| Total Debt | n/a |
| Net Cash | 19.99M |
| Net Cash Per Share | $13.67 |
| Equity (Book Value) | 18.20M |
| Book Value Per Share | 12.45 |
| Working Capital | 18.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -13.41M |
| Capital Expenditures | -28,175 |
| Depreciation & Amortization | 14,918 |
| Net Borrowing | -308,553 |
| Free Cash Flow | -13.44M |
| FCF Per Share | -$9.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,105.07% |
| Shareholder Yield | -1,105.07% |
| Earnings Yield | -153.14% |
| FCF Yield | -183.94% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |